Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK

Tomohiro Nakano, Yuriko Saiki, Chiharu Kudo, Akiyoshi Hirayama, Yasuhiko Mizuguchi, Sho Fujiwara, Tomoyoshi Soga, Makoto Sunamura, Nobutoshi Matsumura, Fuyuhiko Motoi, Michiaki Unno, Akira Horii

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The anti-tumor activity of gemcitabine (GEM) has been clinically proven in several solid tumors, including pancreatic cancer, biliary tract cancer, urinary bladder cancer, and non-small cell lung cancer. However, problems remain with issues such as acquisition of chemoresistance against GEM. GEM is activated after phosphorylation by deoxycytidine kinase (DCK) inside of the cell; thus, DCK inactivation is one of the important mechanisms for acquisition of GEM resistance. We previously investigated the DCK gene in multiple GEM resistant cancer cell lines and identified frequent inactivating mutations. In this study, we identified two crucial genetic alteration in DCK. (1) A total deletion of DCK in RTGBC1-TKB, an acquired GEM resistant cell line derived from a gall bladder cancer cell line TGBC1-TKB. (2) An E197K missense alteration of DCK in MKN28, a gastric cancer cell line; its acquired GEM resistant cancer cell line, RMKN28, showed a loss of the normal E197 allele. We introduced either normal DCK or altered DCK-E197K into RMKN28 and proved that only the introduction of normal DCK restored GEM sensitivity. Furthermore, we analyzed 104 healthy volunteers and found that none of them carried the same base substitution observed in MKN28. These results strongly suggest that (1) the E197K alteration in DCK causes inactivation of DCK, and that (2) loss of the normal E197 allele is the crucial mechanism in acquisition of GEM resistance in RMKN28.

Original languageEnglish
Pages (from-to)1084-1089
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume464
Issue number4
DOIs
Publication statusPublished - 2015 Jul 13

Fingerprint

gemcitabine
Deoxycytidine Kinase
Missense Mutation
Cells
Cell Line
Biliary Tract Neoplasms
Urinary Bladder Neoplasms
Tumors
Neoplasms
Alleles
Urologic Neoplasms
Gallbladder Neoplasms
Phosphorylation

Keywords

  • Chemoresistance
  • Deoxycytidine kinase
  • Gemcitabine
  • MKN28
  • TGBC1-TKB

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK. / Nakano, Tomohiro; Saiki, Yuriko; Kudo, Chiharu; Hirayama, Akiyoshi; Mizuguchi, Yasuhiko; Fujiwara, Sho; Soga, Tomoyoshi; Sunamura, Makoto; Matsumura, Nobutoshi; Motoi, Fuyuhiko; Unno, Michiaki; Horii, Akira.

In: Biochemical and Biophysical Research Communications, Vol. 464, No. 4, 13.07.2015, p. 1084-1089.

Research output: Contribution to journalArticle

Nakano, T, Saiki, Y, Kudo, C, Hirayama, A, Mizuguchi, Y, Fujiwara, S, Soga, T, Sunamura, M, Matsumura, N, Motoi, F, Unno, M & Horii, A 2015, 'Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK', Biochemical and Biophysical Research Communications, vol. 464, no. 4, pp. 1084-1089. https://doi.org/10.1016/j.bbrc.2015.07.080
Nakano, Tomohiro ; Saiki, Yuriko ; Kudo, Chiharu ; Hirayama, Akiyoshi ; Mizuguchi, Yasuhiko ; Fujiwara, Sho ; Soga, Tomoyoshi ; Sunamura, Makoto ; Matsumura, Nobutoshi ; Motoi, Fuyuhiko ; Unno, Michiaki ; Horii, Akira. / Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK. In: Biochemical and Biophysical Research Communications. 2015 ; Vol. 464, No. 4. pp. 1084-1089.
@article{bb98933040d64656b4531c1885959cd4,
title = "Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK",
abstract = "The anti-tumor activity of gemcitabine (GEM) has been clinically proven in several solid tumors, including pancreatic cancer, biliary tract cancer, urinary bladder cancer, and non-small cell lung cancer. However, problems remain with issues such as acquisition of chemoresistance against GEM. GEM is activated after phosphorylation by deoxycytidine kinase (DCK) inside of the cell; thus, DCK inactivation is one of the important mechanisms for acquisition of GEM resistance. We previously investigated the DCK gene in multiple GEM resistant cancer cell lines and identified frequent inactivating mutations. In this study, we identified two crucial genetic alteration in DCK. (1) A total deletion of DCK in RTGBC1-TKB, an acquired GEM resistant cell line derived from a gall bladder cancer cell line TGBC1-TKB. (2) An E197K missense alteration of DCK in MKN28, a gastric cancer cell line; its acquired GEM resistant cancer cell line, RMKN28, showed a loss of the normal E197 allele. We introduced either normal DCK or altered DCK-E197K into RMKN28 and proved that only the introduction of normal DCK restored GEM sensitivity. Furthermore, we analyzed 104 healthy volunteers and found that none of them carried the same base substitution observed in MKN28. These results strongly suggest that (1) the E197K alteration in DCK causes inactivation of DCK, and that (2) loss of the normal E197 allele is the crucial mechanism in acquisition of GEM resistance in RMKN28.",
keywords = "Chemoresistance, Deoxycytidine kinase, Gemcitabine, MKN28, TGBC1-TKB",
author = "Tomohiro Nakano and Yuriko Saiki and Chiharu Kudo and Akiyoshi Hirayama and Yasuhiko Mizuguchi and Sho Fujiwara and Tomoyoshi Soga and Makoto Sunamura and Nobutoshi Matsumura and Fuyuhiko Motoi and Michiaki Unno and Akira Horii",
year = "2015",
month = "7",
day = "13",
doi = "10.1016/j.bbrc.2015.07.080",
language = "English",
volume = "464",
pages = "1084--1089",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK

AU - Nakano, Tomohiro

AU - Saiki, Yuriko

AU - Kudo, Chiharu

AU - Hirayama, Akiyoshi

AU - Mizuguchi, Yasuhiko

AU - Fujiwara, Sho

AU - Soga, Tomoyoshi

AU - Sunamura, Makoto

AU - Matsumura, Nobutoshi

AU - Motoi, Fuyuhiko

AU - Unno, Michiaki

AU - Horii, Akira

PY - 2015/7/13

Y1 - 2015/7/13

N2 - The anti-tumor activity of gemcitabine (GEM) has been clinically proven in several solid tumors, including pancreatic cancer, biliary tract cancer, urinary bladder cancer, and non-small cell lung cancer. However, problems remain with issues such as acquisition of chemoresistance against GEM. GEM is activated after phosphorylation by deoxycytidine kinase (DCK) inside of the cell; thus, DCK inactivation is one of the important mechanisms for acquisition of GEM resistance. We previously investigated the DCK gene in multiple GEM resistant cancer cell lines and identified frequent inactivating mutations. In this study, we identified two crucial genetic alteration in DCK. (1) A total deletion of DCK in RTGBC1-TKB, an acquired GEM resistant cell line derived from a gall bladder cancer cell line TGBC1-TKB. (2) An E197K missense alteration of DCK in MKN28, a gastric cancer cell line; its acquired GEM resistant cancer cell line, RMKN28, showed a loss of the normal E197 allele. We introduced either normal DCK or altered DCK-E197K into RMKN28 and proved that only the introduction of normal DCK restored GEM sensitivity. Furthermore, we analyzed 104 healthy volunteers and found that none of them carried the same base substitution observed in MKN28. These results strongly suggest that (1) the E197K alteration in DCK causes inactivation of DCK, and that (2) loss of the normal E197 allele is the crucial mechanism in acquisition of GEM resistance in RMKN28.

AB - The anti-tumor activity of gemcitabine (GEM) has been clinically proven in several solid tumors, including pancreatic cancer, biliary tract cancer, urinary bladder cancer, and non-small cell lung cancer. However, problems remain with issues such as acquisition of chemoresistance against GEM. GEM is activated after phosphorylation by deoxycytidine kinase (DCK) inside of the cell; thus, DCK inactivation is one of the important mechanisms for acquisition of GEM resistance. We previously investigated the DCK gene in multiple GEM resistant cancer cell lines and identified frequent inactivating mutations. In this study, we identified two crucial genetic alteration in DCK. (1) A total deletion of DCK in RTGBC1-TKB, an acquired GEM resistant cell line derived from a gall bladder cancer cell line TGBC1-TKB. (2) An E197K missense alteration of DCK in MKN28, a gastric cancer cell line; its acquired GEM resistant cancer cell line, RMKN28, showed a loss of the normal E197 allele. We introduced either normal DCK or altered DCK-E197K into RMKN28 and proved that only the introduction of normal DCK restored GEM sensitivity. Furthermore, we analyzed 104 healthy volunteers and found that none of them carried the same base substitution observed in MKN28. These results strongly suggest that (1) the E197K alteration in DCK causes inactivation of DCK, and that (2) loss of the normal E197 allele is the crucial mechanism in acquisition of GEM resistance in RMKN28.

KW - Chemoresistance

KW - Deoxycytidine kinase

KW - Gemcitabine

KW - MKN28

KW - TGBC1-TKB

UR - http://www.scopus.com/inward/record.url?scp=84940459908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940459908&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2015.07.080

DO - 10.1016/j.bbrc.2015.07.080

M3 - Article

C2 - 26196746

AN - SCOPUS:84940459908

VL - 464

SP - 1084

EP - 1089

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 4

ER -